JP2019535829A - 大型薬剤の経皮送達 - Google Patents

大型薬剤の経皮送達 Download PDF

Info

Publication number
JP2019535829A
JP2019535829A JP2019547574A JP2019547574A JP2019535829A JP 2019535829 A JP2019535829 A JP 2019535829A JP 2019547574 A JP2019547574 A JP 2019547574A JP 2019547574 A JP2019547574 A JP 2019547574A JP 2019535829 A JP2019535829 A JP 2019535829A
Authority
JP
Japan
Prior art keywords
skin
composition
antibody
site
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019547574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535829A5 (https=
JPWO2018093465A5 (https=
Inventor
ジョナサン エデルソン，
ジョナサン エデルソン，
Original Assignee
エイリオン セラピューティクス， インコーポレイテッド
エイリオン セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイリオン セラピューティクス， インコーポレイテッド, エイリオン セラピューティクス， インコーポレイテッド filed Critical エイリオン セラピューティクス， インコーポレイテッド
Publication of JP2019535829A publication Critical patent/JP2019535829A/ja
Priority to JP2022134512A priority Critical patent/JP2022164750A/ja
Publication of JP2019535829A5 publication Critical patent/JP2019535829A5/ja
Publication of JPWO2018093465A5 publication Critical patent/JPWO2018093465A5/ja
Priority to JP2024150911A priority patent/JP2024167362A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/068—Microemulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/87—Application Devices; Containers; Packaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Birds (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2019547574A 2016-11-21 2017-09-25 大型薬剤の経皮送達 Withdrawn JP2019535829A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022134512A JP2022164750A (ja) 2016-11-21 2022-08-25 大型薬剤の経皮送達
JP2024150911A JP2024167362A (ja) 2016-11-21 2024-09-02 大型薬剤の経皮送達

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662424937P 2016-11-21 2016-11-21
US62/424,937 2016-11-21
PCT/US2017/053333 WO2018093465A1 (en) 2016-11-21 2017-09-25 Transdermal delivery of large agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022134512A Division JP2022164750A (ja) 2016-11-21 2022-08-25 大型薬剤の経皮送達

Publications (3)

Publication Number Publication Date
JP2019535829A true JP2019535829A (ja) 2019-12-12
JP2019535829A5 JP2019535829A5 (https=) 2024-07-10
JPWO2018093465A5 JPWO2018093465A5 (https=) 2024-07-10

Family

ID=60037726

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019547574A Withdrawn JP2019535829A (ja) 2016-11-21 2017-09-25 大型薬剤の経皮送達
JP2022134512A Pending JP2022164750A (ja) 2016-11-21 2022-08-25 大型薬剤の経皮送達
JP2024150911A Pending JP2024167362A (ja) 2016-11-21 2024-09-02 大型薬剤の経皮送達

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022134512A Pending JP2022164750A (ja) 2016-11-21 2022-08-25 大型薬剤の経皮送達
JP2024150911A Pending JP2024167362A (ja) 2016-11-21 2024-09-02 大型薬剤の経皮送達

Country Status (11)

Country Link
US (2) US11311496B2 (https=)
EP (1) EP3541358A1 (https=)
JP (3) JP2019535829A (https=)
KR (1) KR102487144B1 (https=)
CN (2) CN117731591A (https=)
AU (1) AU2017360346B2 (https=)
CA (1) CA3044219A1 (https=)
IL (1) IL266733A (https=)
MX (2) MX2019005833A (https=)
WO (1) WO2018093465A1 (https=)
ZA (1) ZA201903467B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
AU2017360346B2 (en) * 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
MX2019014349A (es) * 2017-05-31 2020-07-28 Allergan Inc Neurotoxina botulinica para el tratamiento de trastornos asociados con hiperactividad de los melanocitos y/o exceso de melanina.
US20210275691A1 (en) * 2018-05-30 2021-09-09 Allergan, Inc. Screening assay to assess topical delivery of biological therapeutic agents
JP2021535206A (ja) * 2018-08-23 2021-12-16 バーンスタイン，エリック，エフ． 皮膚状態を治療するために抗ｖｅｇｆ化合物を適用するためおよびこのような化合物を使用するためのシステム、デバイスおよび方法
BR112021009554A2 (pt) * 2018-12-03 2021-08-17 Eirion Therapeutics, Inc. aplicação melhorada de agentes grandes
CA3139983A1 (en) * 2019-05-14 2020-11-19 Eirion Therapeutics, Inc. Delaying peak effect and/or extending duration of response
US20220265589A1 (en) * 2021-02-23 2022-08-25 Nanomed Skincare, Inc. Method of administering a dual therapeutic and cosmetic agent
WO2022246184A1 (en) * 2021-05-21 2022-11-24 Veradermics Incorporated Microneedle patch for immunostimulatory drug delivery
WO2023055939A1 (en) * 2021-09-29 2023-04-06 University Of Iowa Research Foundation Apparatus, systems and methods for transdermal drug delivery, permeability enhancement and augmentation
CN116925213B (zh) * 2023-09-12 2024-03-15 中国人民解放军军事科学院军事医学研究院 一种中和a型肉毒毒素的纳米抗体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518307A (ja) * 2005-12-01 2009-05-07 ユニバーシティ オブ マサチューセッツ ロウエル ボツリヌス菌ナノエマルジョン
JP2010502268A (ja) * 2006-08-29 2010-01-28 ナノメド ディヴァイシーズ， インコーポレイテッド 活性物質の経皮送達及びサンプリングのための高アスペクト比マイクロデバイス及びその方法
JP2012514003A (ja) * 2008-12-31 2012-06-21 ルバンス セラピュティックス インク． 注射用ボツリヌス毒素製剤

Family Cites Families (355)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US296006A (en) 1884-04-01 John hoefleb
US3725540A (en) 1970-07-30 1973-04-03 Procter & Gamble Color and odor stabilized dry aerosol antiperspirant
US3964482A (en) * 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
CH587021A5 (https=) 1974-06-07 1977-04-29 Nestle Sa
US4152170A (en) 1975-06-18 1979-05-01 Sumitomo Chemical Company, Ltd. Cross-linked pullulan
JPS541064Y2 (https=) 1975-09-18 1979-01-19
US4172149A (en) 1978-01-30 1979-10-23 Westwood Pharmaceuticals, Inc. Method for treating living skin exhibiting excessive sebum secretion
DE2929425A1 (de) 1979-07-20 1981-02-12 Lothar Kling Vorrichtung fuer injektionsspritzen zur intramuskulaeren und subentanen injektion
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US4908154A (en) 1981-04-17 1990-03-13 Biotechnology Development Corporation Method of forming a microemulsion
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
JPH07116268B2 (ja) 1984-01-09 1995-12-13 大西 靖彦 デキストランの陰イオン性部分置換体とオレフィン化合物との共重合体の製法
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
JPH0798740B2 (ja) 1987-10-28 1995-10-25 日本新薬株式会社 薬物担体
IL88076A (en) 1987-10-28 1993-01-14 Nippon Shinyaku Co Ltd Fat emulsions as drug carriers
US5651991A (en) 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
CH677886A5 (https=) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
FR2659554B1 (fr) 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
US5401243A (en) 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
JP3765579B2 (ja) 1990-08-24 2006-04-12 イーデーエーアー アーゲー 作用物質投与用超微小滴状調剤
JPH04202122A (ja) 1990-11-28 1992-07-22 Procter & Gamble Co:The ジケトン脱臭組成物及び脱臭方法
JPH04198123A (ja) 1990-11-28 1992-07-17 Procter & Gamble Co:The アミン脱臭組成物及び脱臭方法
JPH04198122A (ja) 1990-11-28 1992-07-17 Procter & Gamble Co:The チオールヘテロ環脱臭組成物及び脱臭方法
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5652274A (en) 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
HK1001951A1 (en) 1991-05-03 1998-07-24 Raisio Benecol Ltd. A substance for lowering high cholesterol level in serum and a method for preparing the same
JPH04351623A (ja) 1991-05-28 1992-12-07 Nippon Kayaku Co Ltd 新規ブロック共重合体及びその製造方法
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US6939852B2 (en) 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
US7384918B2 (en) 1991-09-24 2008-06-10 Allergan, Inc. Botulinum toxin for treating muscle contracture
US5613952A (en) 1991-12-23 1997-03-25 Syringe Develpoment Partners Safety syringe
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
IL101387A (en) 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
EP0571677A1 (en) 1992-05-29 1993-12-01 Unilever Plc Aqueous parfume oil microemulsions
EP0572080B1 (en) 1992-05-29 1995-11-15 Quest International B.V. Aqueous perfume oil microemulsions
CA2138020C (en) * 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5470577A (en) 1993-07-07 1995-11-28 Trustees Of Boston University Stimulation of tanning by DNA fragments or single-stranded DNA
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
JPH07285863A (ja) 1994-02-25 1995-10-31 Takeda Chem Ind Ltd 注射剤組成物およびその製造方法
FI963297A7 (fi) 1994-02-25 1996-10-18 Takeda Chemical Industries Ltd Antifungaalisia triatsolijohdannaisia sisältävät emulsiot
DE69529054T2 (de) 1994-02-28 2003-08-21 Nanopharm Ag System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
ES2078190B1 (es) 1994-05-20 1996-08-01 Cusi Lab Procedimiento para el recubrimiento de goticulas o particulas de tamaño nanometrico.
DE69528062T2 (de) 1994-06-20 2003-04-30 Nippon Shinyaku Co., Ltd. Verfahren zum herstellen von emulsionen aus einem emulgator
US5672358A (en) 1994-06-21 1997-09-30 Ascent Pharmaceuticals, Inc. Controlled release aqueous emulsion
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US20020048596A1 (en) 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
FR2730932B1 (fr) 1995-02-27 1997-04-04 Oreal Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69627963T2 (de) 1995-06-06 2004-03-04 Pearce, L. Bruce, Cambridge Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
US5660858A (en) 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
JPH10114648A (ja) 1996-10-11 1998-05-06 Kao Corp 皮膚外用組成物
AU731832B2 (en) 1996-11-12 2001-04-05 Tamarkin Pharmaceutical Innovation Ltd Method for treatment of dermatological disorders
FR2755854B1 (fr) 1996-11-15 1998-12-24 Oreal Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations
KR20000057687A (ko) 1996-12-19 2000-09-25 엔도 마사루 프린트 배선판 및 그 제조방법
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6461596B1 (en) 1997-02-18 2002-10-08 Andrea Taylor Composition and method for promoting hair growth
FR2760970B1 (fr) 1997-03-18 2000-03-10 Oreal Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations
US5994414A (en) 1997-04-28 1999-11-30 Avon Products, Inc. Water-thin emulsion formed by high pressure homogenization process
GB9708066D0 (en) 1997-04-22 1997-06-11 Woolcombers Group Plc Compositions and their use
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
AU3176097A (en) 1997-06-13 1998-12-30 Medinova Medical Consulting Gmbh Drug targeting system, method of its preparation and its use
CN1068524C (zh) 1997-06-23 2001-07-18 叶庆炜 一种治疗顽症牛皮癣的药物
EP1011695B2 (en) 1997-07-15 2009-11-04 The Regents of the University of Colorado Use of neurotoxin therapy for treatment of prostate disorders
US6007856A (en) 1997-08-08 1999-12-28 The Procter & Gamble Company Oil-in-water dispersions of β-carotene and other carotenoids stable against oxidation prepared from water-dispersible beadlets having high concentrations of carotenoid
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US5993852A (en) 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
US6007803A (en) 1997-09-19 1999-12-28 Geltex Pharmaceuticals, Inc. Ionic polymers as toxin binding agents
IT1296914B1 (it) 1997-12-01 1999-08-03 Maria Rosa Gasco Composizione farmaceutica comprendente microparticelle atte al passaggio transmucosale ed al superamento della barriera
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
EP1080720A4 (en) 1998-03-05 2002-06-05 Nippon Shinyaku Co Ltd FAT EMULSIONS FOR INHALATIVE ADMINISTRATION
US5965154A (en) 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
ATE372377T1 (de) 1998-03-30 2007-09-15 Mibelle Ag Cosmetics Verwendung von nanoemulsionen zur bestimmung der biokompatibilität von lipophilen stoffen im zellkultur-test und dafür geeignete nanoemulsionen
FI111513B (fi) 1998-05-06 2003-08-15 Raisio Benecol Oy Uudet fytosteroli- ja fytostanolirasvahappoesterikoostumukset, niitä sisältävät tuotteet sekä menetelmät niiden valmistamiseksi
US5932562A (en) 1998-05-26 1999-08-03 Washington University Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same
US6503231B1 (en) * 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
FR2783169B1 (fr) 1998-09-15 2001-11-02 Sederma Sa Utilisation cosmetique ou dermopharmaceutique de peptides pour la cicatrisation et pour l'amelioration de l'aspect cutane lors du vieillissement naturel ou accelere (heliodermie, pollution)
US6242001B1 (en) 1998-11-30 2001-06-05 Mcneil-Ppc, Inc. Method for producing dispersible sterol and stanol compounds
DE19856897A1 (de) 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
JP2002533379A (ja) 1998-12-23 2002-10-08 イデア アクチェンゲゼルシャフト 生体内における局所的に非侵襲性である用途のための改善された製剤
FR2787728B1 (fr) 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2788007B1 (fr) 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US20030229141A1 (en) 1999-01-08 2003-12-11 Yu Ruey J. N-acetyl cysteine and its topical use
AU2963400A (en) 1999-01-14 2000-08-01 Amcol International Corporation Improved controlled release compositions and method
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US20020054914A1 (en) 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US20040009936A1 (en) 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
EP1100475A1 (en) 1999-06-02 2001-05-23 Medinova Medical Consulting Gmbh Use of drug-loaded nanoparticles for the treatment of cancers
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
JP2003501376A (ja) 1999-06-04 2003-01-14 スカイファーマ インコーポレーテッド 疎水性薬物の持続性放出のための油コア組成物
US6256533B1 (en) * 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
WO2001010413A2 (en) 1999-08-04 2001-02-15 Idea Ag Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers
US6358917B1 (en) 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6429189B1 (en) 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
WO2001047561A1 (en) 1999-12-28 2001-07-05 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
US6898427B1 (en) 1999-12-29 2005-05-24 Bellsouth Intellectual Property Corporation Method of coupling portable communications device to first network by way of second network
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
FR2804015B1 (fr) 2000-01-21 2005-12-23 Oreal Nanoemulsion contenant des lipides amphiphiles et un polymere non ionique et utilisations
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
FR2805761B1 (fr) 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
MXPA02009275A (es) 2000-03-23 2004-09-06 Collaborative Technologies Inc Metodo para preparar dispersiones de alta presion/alto esfuerzo cortante que contienen ingredientes fisiologicamente activos.
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
FR2809112B1 (fr) 2000-05-16 2004-05-07 Centre Nat Rech Scient Materiaux a base de polymeres biodegradables et son procede de preparation
FR2809010B1 (fr) 2000-05-22 2002-07-12 Oreal Nanoemulsion a base de polymeres anioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
US6670322B2 (en) 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20020155084A1 (en) 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
FR2811561B1 (fr) 2000-07-13 2003-03-21 Oreal Composition, notamment cosmetique, renfermant la dhea et/ou un precurseur ou derive chimique ou biologique de celle-ci, et un inhibiteur de metalloproteinase
US20040220100A1 (en) 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US6455058B1 (en) 2000-09-13 2002-09-24 Amitee Cosmetics, Inc. Composition and method for hair and scalp treatment
CA2427858A1 (en) 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
FR2816949B1 (fr) 2000-11-17 2003-11-28 Centre Nat Rech Scient Copolymere a structure sequencee compose d'un segment saccharidique lie a au moins un segment hydrophobe bioerodable, et particules correspondantes
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
DK1345597T3 (da) 2000-12-27 2007-12-10 Ares Trading Sa Amfifile lipidanopartikler til peptid- og/eller proteininkorporering
FI20010115A0 (fi) 2001-01-18 2001-01-18 Orion Corp Menetelmä nanopartikkelien valmistamiseksi
FR2819427B1 (fr) 2001-01-18 2003-04-11 Oreal Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US8216797B2 (en) 2001-02-07 2012-07-10 Massachusetts Institute Of Technology Pathogen detection biosensor
US20030072841A1 (en) 2001-03-19 2003-04-17 The Procter & Gamble Campany Polybutene containing chewing gum and confection
CA2445125A1 (en) 2001-03-21 2002-10-03 University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
US20040048836A1 (en) 2001-03-23 2004-03-11 Wilmott James M Method for preparing high pressure/ high shear dispersions containing physiologically active ingredients
EP1377255A4 (en) 2001-03-30 2008-11-19 Color Access Inc NEW NANOEMULSIONS
KR100463167B1 (ko) 2001-04-13 2004-12-23 주식회사 태평양 고분자 나노입자를 이용한 경피흡수제 및 이를 함유한외용제 조성물
WO2004030608A2 (en) 2001-06-05 2004-04-15 The Regents Of The University Of Michigan Nanoemulsion vaccines
US6767341B2 (en) * 2001-06-13 2004-07-27 Abbott Laboratories Microneedles for minimally invasive drug delivery
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
KR100566911B1 (ko) 2001-06-25 2006-04-03 주식회사 삼양사 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체
US7226605B2 (en) 2001-07-27 2007-06-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
US7063860B2 (en) 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US20150037402A1 (en) 2001-08-13 2015-02-05 Lipella Pharmaceuticals, Inc. Methods and Compositions for Treating Gastric Disorders
DE10146647A1 (de) 2001-09-21 2003-04-24 Marc Heckmann Arzneimittel zur Prophylaxe und Therapie von Bromhidrosis
US20030077240A1 (en) 2001-10-24 2003-04-24 Clariant International, Ltd. Use of high-purity phenylsilsesquioxane liquids for the preparation of cosmetic and pharmaceutical compositions
US7235230B2 (en) 2001-10-24 2007-06-26 Clariant Finance (Bvi) Limited Leave-on compositions for personal care
CA2465123A1 (en) 2001-10-30 2003-05-08 Pentapharm Ag Dermopharmaceutically and cosmetically active oligopeptides
US6745211B2 (en) * 2001-11-21 2004-06-01 Ge Financial Assurance Holdings, Inc. Method and system for verifying and correcting data records in a database
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US6765001B2 (en) 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
KR100441167B1 (ko) 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
US6908453B2 (en) 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
EP1334729A1 (en) 2002-02-07 2003-08-13 Botulinum Toxin Research Associates, Inc. Therapeutic use of non-neurotoxic clostridium botulinum toxin type C2
WO2003071267A1 (en) 2002-02-19 2003-08-28 Vanderbilt University Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors
US6861066B2 (en) 2002-03-11 2005-03-01 Health Plus International Inc. Method for the delivery of a biologically active agent
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US6623780B1 (en) 2002-03-26 2003-09-23 Cargill, Inc. Aqueous dispersible sterol product
US20040115159A1 (en) 2002-03-29 2004-06-17 Tadlock Charles C Novel nanoemulsions
US6875438B2 (en) 2002-04-27 2005-04-05 Aventis Pharma Deutschland Gmbh Preparations for topical administration of substances having antiandrogenic activity
US20060083778A1 (en) 2002-05-03 2006-04-20 Dean Allison Controlled release compositions of estradiol metabolites
EP1509236A4 (en) 2002-05-13 2008-07-30 Children S Hospital Los Angele TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US7459164B2 (en) 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
WO2003101483A1 (en) 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
CA2488617A1 (en) 2002-06-10 2003-12-18 Eugene R. Cooper Nanoparticulate sterol formulations and sterol combinations
MXPA04012567A (es) 2002-06-11 2005-04-19 Ethypharm Sa Nanocapsulas lipidicas encubiertas, metodos para la preparacion de las mismas y uso de las mismas como un portador para principios activos.
US6996748B2 (en) 2002-06-29 2006-02-07 Intel Corporation Handling faults associated with operation of guest software in the virtual-machine architecture
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
JP4824311B2 (ja) 2002-09-12 2011-11-30 スリーエム イノベイティブ プロパティズ カンパニー 低温特性および耐溶剤性を有するフルオロエラストマー
EP1590034B1 (en) * 2002-10-07 2014-05-14 Biovalve Technologies, Inc. Microneedle array patch
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US20070292359A1 (en) 2002-10-25 2007-12-20 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20040115727A1 (en) 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
DE10258960A1 (de) 2002-12-16 2004-07-01 Henkel Kgaa Nanoskalige Hydrogele gegen Falten, raue und trockene Haut
US7329688B2 (en) 2002-12-17 2008-02-12 Soft Gel Technologies, Inc. Natural vitamin E compositions with superior antioxidant potency
CA2510058C (en) 2002-12-20 2010-03-16 Botulinum Toxin Research Associates, Inc. Improved pharmaceutical botulinum toxin compositions
FR2849375B1 (fr) 2002-12-30 2006-10-20 Jean Noel Thorel Compositions cosmetiques, par exemple pour traiter le vieillissement cutane photo-induit
US7390505B2 (en) 2003-01-31 2008-06-24 Elan Pharma International, Ltd. Nanoparticulate topiramate formulations
EP1594552A2 (en) 2003-02-05 2005-11-16 Amphora Discovery Corporation Topical delivery of cosmetic agents
EP1599213A4 (en) 2003-02-24 2009-07-15 Ira Sanders CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20040247623A1 (en) 2003-03-24 2004-12-09 Roger Cady Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US20040191330A1 (en) 2003-03-31 2004-09-30 Keefe Candace R. Daily skin care regimen
AU2004226605A1 (en) 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
KR100720213B1 (ko) 2003-04-04 2007-05-21 화이자 프로덕츠 인코포레이티드 미세 유동화된 수중 유적형 유화액 및 백신 조성물
PL3524611T3 (pl) 2003-05-20 2021-06-14 Immunogen, Inc. Udoskonalone czynniki cytotoksyczne zawierające nowe maitansynoidy
GB0312309D0 (en) 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
US20050079228A1 (en) 2003-05-30 2005-04-14 Ashish Jaiswal Clear, stable topical compositions of clarithromycin and processes for their preparation
AU2004273779B2 (en) 2003-06-04 2009-10-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
WO2004112821A1 (ja) 2003-06-20 2004-12-29 Santen Pharmaceutical Co., Ltd. 筋緊張亢進性疾患の治療剤
EP1720605A4 (en) 2003-06-23 2007-10-24 Transpharma Medical Ltd TRANSDERMAL DELIVERY SYSTEM FOR COSMETIC AGENTS
US20050013850A1 (en) 2003-07-15 2005-01-20 Caers Jan K. Device to assist hyperhydrosis therapy
WO2005013938A1 (ja) 2003-08-06 2005-02-17 Eisai Co., Ltd. 薬物超微粒子の製造法及び製造装置
WO2005014051A1 (en) 2003-08-08 2005-02-17 Barnes-Jewish Hospital Emulsion particles for imaging and therapy and methods of use thereof
US7419996B2 (en) 2003-08-13 2008-09-02 The University Of Houston Parenteral and oral formulations of benzimidazoles
CH715855B1 (de) 2003-08-28 2020-08-14 Mibelle Ag Zubereitung bestehend aus mindestens zwei Nanoemulsionen.
EP1510206A1 (en) 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
JP2006199589A (ja) 2003-09-03 2006-08-03 Ltt Bio-Pharma Co Ltd 生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤
US7160699B2 (en) 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
BRPI0415858A (pt) 2003-10-29 2007-01-09 Sonus Pharma Inc compostos de medicamentos terapêuticos modificados por tocoferol
JP4256389B2 (ja) 2003-11-17 2009-04-22 セダーマ テトラペプチドとトリペプチドの混合物を含む組成物
NO20035681D0 (no) 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av lungekreft
US20050136024A1 (en) 2003-12-22 2005-06-23 Stockel Richard F. Dermatological compositions
EP1547674A1 (en) 2003-12-23 2005-06-29 MediGene Oncology GmbH Method for producing colloidal nanoparticles
US6974579B2 (en) 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
FR2865131B1 (fr) 2004-01-15 2007-08-24 Gattefosse Ets Sa Utilisation d'un extrait d'acmella oleracea pour son effet botox like dans une composition cosmetique anti-rides
EP1713446B1 (en) 2004-01-23 2010-12-01 Camurus Ab Ternary non-lamellar lipid compositions
WO2005074894A1 (en) 2004-01-30 2005-08-18 Corium International Rapidly dissolving film for delivery of an active agent
JP2007520555A (ja) 2004-02-05 2007-07-26 バクスター・インターナショナル・インコーポレイテッド 自己安定化剤の使用により調製された分散剤
EP1718163A1 (en) 2004-02-23 2006-11-08 The Texas A&M University System Antioxidant compositions and methods of use thereof
DE102004009287A1 (de) 2004-02-26 2005-09-15 Institut Für Neue Materialien Gem. Gmbh Amphiphile Nanopartikel
CN1946431B (zh) 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
US20050214325A1 (en) 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
BRPI0509019A (pt) 2004-03-22 2007-08-07 Celgene Corp métodos para tratar, prevenir ou controlar um distúrbio ou doença de pele, para tratar, prevenir ou controlar ceratose senil e para tratar ou controlar ceratose, composição farmacêutica, forma de dosagem unitária individual, e, kit
DE102004016710B4 (de) 2004-04-05 2020-11-19 Greppmayr GmbH Formulierung zur Fußpflege
EP1586336A1 (en) 2004-04-06 2005-10-19 JOHNSON & JOHNSON GmbH Compositions containing copper salts and soy products
TW200603843A (en) 2004-04-20 2006-02-01 Technology Dev Company Ltd Tissue enhancement implant and method
US20050249686A1 (en) 2004-04-27 2005-11-10 Francoise Pataut Cosmetic composition free of water comprising fatty acid esters, petrolatum oil and non-ionic polymers
US7591806B2 (en) 2004-05-18 2009-09-22 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
US7228259B2 (en) 2004-06-30 2007-06-05 Lucent Technologies Inc. Method and apparatus for structure-preserving reduced-order modeling
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
AU2005275193A1 (en) 2004-07-15 2006-02-23 Nanobac Life Sciences Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses
BRPI0513850A (pt) 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
KR100623013B1 (ko) 2004-09-04 2006-09-19 김영대 나노에멀션, 그의 용도 및 제조방법
CA2518650A1 (en) 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
AU2005286640A1 (en) 2004-09-21 2006-03-30 Anesiva, Inc. Delivery of polynucleotides
US20060073208A1 (en) 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
WO2006040688A2 (en) 2004-10-12 2006-04-20 Ernir Snorrason Inhibitors of acetylcholinesterase for treating skin diseases
US20060084353A1 (en) 2004-10-18 2006-04-20 Wong Tak K Reversible ball having hyper-elastic properties
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
BRPI0404595A (pt) 2004-10-26 2006-06-13 Natura Cosmeticos Sa nanoemulsão óleo-em-água, composição cosmética e produto cosmético compreendendo a mesma, processo para preparação da dita nanoemulsão
JP2008519784A (ja) 2004-11-12 2008-06-12 イデア アクチェンゲゼルシャフト 皮膚状態の治療における拡張表面凝集体
EP1848407A2 (en) 2005-02-02 2007-10-31 Mega Lifesciences Pvt. Ltd. Oral pharmaceutical composition
US7838011B2 (en) 2005-02-14 2010-11-23 Pankaj Modi Stabilized protein compositions for topical administration and methods of making same
PL1853303T3 (pl) 2005-02-14 2016-05-31 Dpm Therapeutics Corp Stabilizowane kompozycje do podawania miejscowego i sposoby ich otrzymywania
CA2494473C (en) 2005-02-14 2007-06-26 Dpm Therapeutics Corp. Stabilized protein compositions for topical administration and methods of making same
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
US20080220021A1 (en) 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
US9314431B2 (en) 2005-02-14 2016-04-19 Transdermal Corp Solubilized benzoyl small molecule
CN101160318A (zh) 2005-03-03 2008-04-09 雷文斯治疗公司 用于局部施用和经皮肤递送寡肽的组合物和方法
SG160357A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP4444149B2 (ja) 2005-03-30 2010-03-31 株式会社ナリス化粧品 超微細エマルジョンで構成される皮膚外用剤
US8926991B2 (en) 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
CA2948238A1 (en) 2005-06-14 2006-12-28 Revance Therapeutics, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US8105611B2 (en) 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
BRPI0613631A8 (pt) 2005-07-18 2017-12-26 Univ Massachusetts Lowell nanoemulsão e método,
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
WO2007015441A1 (ja) * 2005-08-01 2007-02-08 Hisamitsu Pharmaceutical Co., Inc. 経皮または経粘膜投与のためのアジュバントおよび製剤
JP2009504805A (ja) 2005-08-09 2009-02-05 ナノバイオ コーポレーション 抗炎症活性を有するナノエマルジョン組成物
WO2007035311A2 (en) 2005-09-16 2007-03-29 University Of Massachusetts Lowell Anti-oxidant synergy formulation nanoemulsions to treat cancer
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
EP1933813A4 (en) 2005-10-11 2013-02-27 Univ Pittsburgh SPHINGOMYELIN LIPOSOME FOR THE TREATMENT OF HYPERACTIVE BLADDER DISORDER
DE102006046076A1 (de) 2005-10-14 2007-04-19 Henkel Kgaa Kosmetische und dermatologische Zusammensetzungen mit Oligopeptiden und Apfelextrakt
CN101340884A (zh) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
CN101304738A (zh) 2005-11-09 2008-11-12 霍尔莫斯医疗有限公司 非培米芬的制剂
US20070148194A1 (en) 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US20070178121A1 (en) 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
JP2009527275A (ja) 2006-02-17 2009-07-30 ゾゲニクス インコーポレーティッド 神経毒の送達のための方法およびシステム
US7939567B2 (en) 2006-02-24 2011-05-10 Blue Blood Biotech Corp. Dextromethorphan-based method for treating acne
EP1998742A2 (en) 2006-03-08 2008-12-10 Nuviance, INC. Transdermal drug delivery compositions and topical compositions for application on the skin
EP2015773A4 (en) 2006-04-27 2010-05-05 Anterios Inc EXAMINATION OF THE EFFECTS OF TOPICAL ADMINISTRATION OF CHEMICALLY DENOMINATING PHARMACEUTICALS
US20110135742A1 (en) 2006-06-20 2011-06-09 The Regents Of The University Of California Controlled release encapsulated anti-bacterial and anti-inflammatory nanoparticles
PT2494959E (pt) 2006-07-05 2015-02-20 Foamix Pharmaceuticals Ltd Veículo formador de espuma de ácido dicarboxílico e suas composições farmacêuticas
US20100183726A1 (en) 2006-08-02 2010-07-22 Robert Nicolosi Compositions and methods for treating cancer with dacarbazine nanoemulsions
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
US7445783B2 (en) 2006-10-30 2008-11-04 Cappellos, Inc. Topical and transdermal treatments using urea formulations
EP2073794A2 (en) 2006-11-14 2009-07-01 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
SG10201607909WA (en) 2006-12-01 2016-11-29 Anterios Inc Peptide nanoparticles and uses therefor
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
US9364461B2 (en) 2006-12-21 2016-06-14 Santen Sas Process for manufacturing ophthalmic oil-in-water emulsions
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
US9511016B2 (en) 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
JP5101693B2 (ja) 2007-06-20 2012-12-19 コンパニー ゼネラール デ エタブリッスマン ミシュラン 多車軸車両の全タイヤｉｄのオートロケーション
WO2009009417A2 (en) 2007-07-06 2009-01-15 Wyeth Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
CN101842107B (zh) * 2007-07-26 2014-04-23 雷文斯治疗公司 抗微生物肽，组合物和使用方法
US20120150023A1 (en) 2007-08-06 2012-06-14 Kaspar Roger L Microneedle arrays for active agent delivery
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
EP2630966B1 (en) 2007-10-12 2017-04-19 Massachusetts Institute of Technology Vaccine nanotechnology
EP2227766A2 (en) 2007-11-05 2010-09-15 Wista Laboratories Ltd. Systems for clinical trials
TWI543768B (zh) 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
CA2719803A1 (en) 2008-03-28 2009-10-01 University Of Massachusetts Compositions and methods for the preparation of nanoemulsions
US20170361130A9 (en) 2008-05-23 2017-12-21 Pankaj Modi Stabilized and solubilized drug formulation for topical application and transdermal efficacy for cosmetic improvement and methods of formulation
AU2009248810B2 (en) 2008-05-23 2013-12-05 The Regents Of The University Of Michigan Nanoemulsion vaccines
EP2293814A4 (en) 2008-05-23 2013-02-13 Univ Michigan NANOEMULSION AGENTS
MX379265B (es) 2008-06-26 2025-03-11 Anterios Inc Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.
WO2010025128A1 (en) 2008-08-25 2010-03-04 Critical Biologics Corporation Methods for reducing sample size of clinical trials
US20110206736A1 (en) 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
ES2342754B1 (es) 2008-10-03 2011-05-11 Lipotec, S.A. Peptidos utiles en el tratamiento y/o cuidado de la piel, mucosas, cuero cabelludo y/o cabello y su uso en composiciones cosmeticas o farmaceuticas.
JP5879126B2 (ja) * 2008-10-07 2016-03-08 ジン・トゥオＪＩＮ Ｔｕｏ 相転移ポリマーマイクロニードル
WO2010056922A2 (en) * 2008-11-12 2010-05-20 Kythera Biopharmaceuticals, Inc. Systems and methods for delivery of biologically active agents
US20100137357A1 (en) 2008-11-26 2010-06-03 Koleng John J Compositions and methods for hyperhidrosis
US20100226983A1 (en) 2009-01-28 2010-09-09 Nanobio Corporation Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
ES2349972B1 (es) 2009-02-16 2011-11-24 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosméticas o farmacéuticas.
US20130045238A1 (en) 2009-04-22 2013-02-21 Agency For Science, Technology And Research Emulsions for transdermal delivery
NZ613647A (en) 2009-05-06 2015-02-27 Biotest Ag Uses of immunoconjugates targeting cd138
EP2445521A4 (en) * 2009-06-25 2015-08-26 Revance Therapeutics Inc ALBUMINE-FREE BOTULINUM TOXIN FORMULATIONS
US9125907B2 (en) 2009-09-30 2015-09-08 Christopher Shaari Use of botulinum neurotoxin to treat substance addictions
WO2011050180A1 (en) 2009-10-21 2011-04-28 Immunogen, Inc. Novel dosing regimen and method of treatment
EP2529222A4 (en) 2010-01-26 2013-10-09 Ridge Diagnostics Inc MULTIPLE BIOMARKER PANELS FOR STRATIFYING ILLNESS HEAVY GRADES AND MONITORING THE TREATMENT OF DEPRESSIONS
EP2575872B1 (en) 2010-06-01 2020-08-19 Seqirus UK Limited Concentration of influenza vaccine antigens without lyophilization
US20110305735A1 (en) 2010-06-09 2011-12-15 Lipotec, S.A. Skin antiaging treatment
US20130078295A1 (en) 2010-06-09 2013-03-28 Lipotec S.A. Skin antiaging treatment
US20120064136A1 (en) 2010-09-10 2012-03-15 Nanobio Corporation Anti-aging and wrinkle treatment methods using nanoemulsion compositions
ES2390033B1 (es) 2010-11-30 2013-10-31 Lipotec S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas.
EP2667854B1 (en) 2011-01-24 2019-01-16 Anterios, Inc. Nanoparticle compositions
CN103533926A (zh) 2011-01-24 2014-01-22 安特里奥公司 空纳米颗粒组合物及其用于治疗皮肤病学病症的用途
KR20140004186A (ko) 2011-01-24 2014-01-10 안테리오스, 인코퍼레이티드 표면활성제 조성물
US20120328549A1 (en) 2011-01-24 2012-12-27 Anterios, Inc. Oil compositions
JP2014507420A (ja) 2011-01-24 2014-03-27 アンテリオス， インコーポレイテッド パラベン組成物
KR20140005998A (ko) 2011-01-24 2014-01-15 안테리오스, 인코퍼레이티드 나노입자 조성물, 이의 제형, 및 그의 용도
BR112013020770A2 (pt) 2011-02-15 2019-08-27 Allergan, Inc. composições de creme farmacêutico de oximetazolina para tratamento de sintomas de rosácea
AU2012283968B2 (en) 2011-07-20 2016-04-14 Allergan, Inc. Botulinum toxins for use in a method for treatment of adipose deposits
EP2550975A1 (en) 2011-07-29 2013-01-30 Sanofi Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab
WO2013096026A1 (en) 2011-12-21 2013-06-27 3M Innovative Properties Company Transdermal adhesive patch assembly with removable microneedle array and method of using same
CN104127859B (zh) 2011-12-27 2015-08-19 中国药科大学 多肽在制备治疗或预防类风湿性关节炎药物中的应用
AU2013234988A1 (en) 2012-03-22 2014-10-09 Revance Therapeutics, Inc. Method of treatment of wrinkles using topical chemodenervating agents
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
AU2013248301B2 (en) 2012-04-16 2017-11-09 Lubrizol Advanced Materials, Inc. Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions
WO2015020982A2 (en) 2013-08-04 2015-02-12 Aquavit Pharmaceuticals, Inc. Direct application system and method for the delivery of bioactive compositions and formulations
CA2889833A1 (en) * 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
EP2792684A1 (en) 2013-04-15 2014-10-22 Lipotec, S.A. Compounds useful in the treatment and/or care of the skin and their cosmetic or pharmaceutical compositions
CN103479627A (zh) 2013-05-16 2014-01-01 武汉光谷百桥国际生物科技有限公司 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用
WO2015168564A1 (en) 2014-05-01 2015-11-05 Anterios, Inc. Methods to treat, prevent, and improve skin conditions
AU2015252947B2 (en) 2014-05-01 2020-07-09 Anterios, Inc. Demonstrable efficacy across or within patient populations
CN115998740A (zh) 2014-10-29 2023-04-25 萨姆森临床私人有限公司 毛发过度脱落的检测和治疗
AU2016343748A1 (en) 2015-10-29 2018-05-17 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
US20170209553A1 (en) 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
BR112021004542A2 (pt) 2018-09-13 2021-06-08 Eirion Therapeutics, Inc. inibidores do inibidor de ativador de plasminogênio 1 (pai-1) e usos para os mesmos
CA3112549A1 (en) 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
BR112021009554A2 (pt) 2018-12-03 2021-08-17 Eirion Therapeutics, Inc. aplicação melhorada de agentes grandes
CA3139983A1 (en) 2019-05-14 2020-11-19 Eirion Therapeutics, Inc. Delaying peak effect and/or extending duration of response

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518307A (ja) * 2005-12-01 2009-05-07 ユニバーシティ オブ マサチューセッツ ロウエル ボツリヌス菌ナノエマルジョン
JP2010502268A (ja) * 2006-08-29 2010-01-28 ナノメド ディヴァイシーズ， インコーポレイテッド 活性物質の経皮送達及びサンプリングのための高アスペクト比マイクロデバイス及びその方法
JP2012514003A (ja) * 2008-12-31 2012-06-21 ルバンス セラピュティックス インク． 注射用ボツリヌス毒素製剤

Also Published As

Publication number Publication date
CA3044219A1 (en) 2018-05-24
KR102487144B1 (ko) 2023-01-12
JP2024167362A (ja) 2024-12-03
AU2017360346B2 (en) 2023-11-23
ZA201903467B (en) 2022-12-21
US11311496B2 (en) 2022-04-26
JP2022164750A (ja) 2022-10-27
BR112019010131A2 (pt) 2019-10-08
CN117731591A (zh) 2024-03-22
WO2018093465A1 (en) 2018-05-24
CN110198703A (zh) 2019-09-03
MX2019005833A (es) 2019-10-30
EP3541358A1 (en) 2019-09-25
US20220218623A1 (en) 2022-07-14
US20190343773A1 (en) 2019-11-14
MX2023006706A (es) 2023-06-20
AU2017360346A1 (en) 2019-06-13
KR20190087517A (ko) 2019-07-24
IL266733A (en) 2019-07-31

Similar Documents

Publication Publication Date Title
US20220218623A1 (en) Transdermal delivery of large agents
JP6841736B2 (ja) ボツリヌス菌ナノエマルジョン
KR101848095B1 (ko) 경피 운반
JP2024170568A (ja) 大型薬物の送達改善
JP2025118791A (ja) ピーク効果の遅延および／または応答持続時間の延長
HK40110119A (zh) 大试剂的透皮递送
HK40060152A (en) Improved delivery of large agents
HK40013656A (en) Transdermal delivery of large agents
BR112019010131B1 (pt) Composição de nanoemulsão, emplastro, kit e uso de um agente grande que tem um peso molecular de 100.000 da ou maior no condicionamento da pele e para tratar distúrbios dermatológicos
BR122025013906A2 (pt) Composição de agentes grandes, emplastro, kit e seus usos transdérmicos
HK40070640A (en) Delaying peak effect and/or extending duration of response

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200923

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200923

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210726

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220825

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220825

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220909

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221017

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221018

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221118

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240515

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240625

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250314